1-(4-methylphenylsulphonyl)-4-(4-methylphenylsulphonyloxymethyl)piperidine | 136704-06-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-methylphenylsulphonyl)-4-(4-methylphenylsulphonyloxymethyl)piperidine
• 英文别名: (1-tosylpiperidin-4-yl)methyl 4-methylbenzenesulfonamide；(1-Tosylpiperidin-4-yl)methyl 4-methylbenzenesulfonate；[1-(4-methylphenyl)sulfonylpiperidin-4-yl]methyl 4-methylbenzenesulfonate
• CAS: 136704-06-8
• 化学式: C₂₀H₂₅NO₅S₂
• 分子量: 423.554
• InChiKey: BSMGLGJSTKGYDR-UHFFFAOYSA-N

物化性质

• 沸点：
  585.3±52.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  97.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(4-methylphenylsulphonyl)-4-(4-methylphenylsulphonyloxymethyl)piperidine 在 sodium azide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 4-(azidomethyl)-1-(4-methylphenyl)sulfonylpiperidine
  参考文献：
  名称：

  WO2008/73623

  摘要：

  公开号：
• 作为产物：
  描述：

  4-哌啶甲醇 、 对甲苯磺酰氯 生成 1-(4-methylphenylsulphonyl)-4-(4-methylphenylsulphonyloxymethyl)piperidine
  参考文献：
  名称：

  [EN] NEW ARYLPIPERAZINYL COMPOUNDS
  [FR] NOUVEAUX COMPOSES D'ARYLPIPERAZINYLE

  摘要：

  公开号：

  WO2004069794A3

文献信息

• Muscarinic receptor antagonists
  申请人：Pfizer Inc.

  公开号：US05607950A1

  公开（公告）日：1997-03-04

  The invetion is a method of treating irritable bowel syndrome with a compound selected from the formula ##STR1## wherein R, R.sup.1, m, n p are as defined in the specification, or a pharmaceutically acceptable salt thereof.

  这项发明是一种治疗肠易激综合征的方法，所使用的化合物从公式 ##STR1## 中选择，其中R、R.sup.1、m、n和p如规范中定义，或其药用盐。
• Reductive amidation of alkyl tosylates with isocyanates by a Ni/Co-dual catalytic system
  作者：Takuya Michiyuki、Itaru Osaka、Kimihiro Komeyama

  DOI：10.1039/c9cc09377j

  日期：——

  Reductive amidation of alkyl tosylates with isocyanates using the Ni/Co-dual catalytic system is disclosed. The method proceeds efficiently under mild conditions, giving rise to the corresponding alkyl amides. Notably, the protocol can discriminate the steric environment of two alkyl tosylate moieties, enabling regioselective mono-amidation at the less-bulky site.

  公开了使用Ni / Co-双催化体系对甲苯磺酸烷基酯与异氰酸酯的还原酰胺化。该方法在温和条件下有效地进行，得到相应的烷基酰胺。值得注意的是，该协议可以区分两个甲苯磺酸烷基酯部分的空间环境，从而在较小的位点实现区域选择性单酰胺化。
• Arylpiperazinyl compounds
  申请人：——

  公开号：US20040220192A1

  公开（公告）日：2004-11-04

  The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂或拮抗剂。公开了由公式I表示的新型芳基哌嗪磺酰胺化合物及其合成和用于治疗直接或间接由5-HT受体介导的疾病的用途。这些疾病包括中枢神经系统疾病，如广泛性焦虑症、ADD/ADHD、神经损伤、中风和偏头痛。还包括制备方法、新型中间体和其制药盐。
• SOLUBLE EPOXIDE HYDROLASE INHIBITORS
  申请人：Patel Dinesh

  公开号：US20080200467A1

  公开（公告）日：2008-08-21

  Disclosed are alpha keto amide and alpha hydroxy amide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases.

  本发明涉及抑制可溶性环氧水解酶（sEH）的α酮酰胺和α羟基酰胺化合物和组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物治疗患者的方法。这些化合物、组合物和方法可用于治疗各种sEH介导的疾病，包括高血压、心血管、炎症、肺部和糖尿病相关疾病。
• Arylpiperazinyl Compounds
  申请人：Dhanoa S. Dale

  公开号：US20080027066A1

  公开（公告）日：2008-01-31

  The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂或拮抗剂。公开了由式I表示的新型芳基哌嗪磺酰胺化合物及其合成和用途，用于治疗包括直接或间接通过5-HT受体介导的疾病。这些疾病包括中枢神经系统疾病，如广泛性焦虑症，ADD / ADHD，神经损伤，中风和偏头痛。还包括制备方法、新型中间体和药物盐。